CPG
VRTX icon

Custom Portfolio Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Custom Portfolio Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		$98.4K Hold
210
– – 0.08% 75
2024
Q1 		$87.8K Hold
210
– – 0.07% 79
2023
Q4 		$85.4K Buy
+210
New +$77.6K 0.08% 70

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Custom Portfolio Group's VRTX Position: Q2 2024 in Review

Custom Portfolio Group held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2024 at 210 shares worth $98.4K. The position accounts for 0.08% of the portfolio, ranked #75.

Custom Portfolio Group first reported a position in VRTX in Q4 2023 and has held it in 3 quarters since. 1,549 funds tracked by Wall St. Rank hold VRTX as of Q2 2024.

  • Custom Portfolio Group held 210 shares of Vertex Pharmaceuticals worth $98.4K as of Q2 2024.
  • Custom Portfolio Group left its Vertex Pharmaceuticals share count unchanged in Q2 2024.
  • Vertex Pharmaceuticals made up 0.08% of Custom Portfolio Group's portfolio in Q2 2024, its #75 holding.
  • Custom Portfolio Group first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 3 quarters since.
  • 1,549 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2024.

Based on Custom Portfolio Group's 13F filing for Q2 2024, filed 27 Aug 2024.